Fig. 5: In vitro evaluation of pan-FGFR inhibitors in preventing recurrence following combination chemotherapy.
From: Targeting PEA3 transcription factors to mitigate small cell lung cancer progression
A Generalized FGFR intracellular signaling pathway. B Experimental scheme for kinase inhibitor evaluation. C Viable cell counts at 21 days following 500 nM cisplatin and etoposide challenge across three SCLC cell lines: H146, H524, and H526. D Evaluation of single agent cytotoxicity of pan-FGFR inhibitors at 3 day and 7 day time points across three SCLC cell lines: H209, H524, and H526. E Dual titrations of pan-FGFR inhibitors infigratininb and erdafitinib against cabozantinib in H82 (left) and H526 (right).
